We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Next Generation Sequencing for Routine Clinical Diagnostics
News

Next Generation Sequencing for Routine Clinical Diagnostics

Next Generation Sequencing for Routine Clinical Diagnostics
News

Next Generation Sequencing for Routine Clinical Diagnostics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Next Generation Sequencing for Routine Clinical Diagnostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM™ analytics platform with IDT’s NGS target capture products. The new bundle will create the most advanced NGS data analytics platform in the market.

With these bundle solutions, Sophia Genetics will address the needs of European hospitals that are moving from small panels (1–20 genes) to medium panels (21–200 genes). The collaboration between the companies has produced a superior NGS target capture system that combines top analytical performance, high sample throughput, and flexibility. 

Jurgi Camblong, CEO and founder of Sophia Genetics, commented, “The NGS bundle solutions are a true game changer for hospitals, relieving them of the burden of testing multiple NGS enrichment technologies.

Having evaluated a large number of DNA enrichment technologies, we can now offer hospitals validated solutions that combine best-in-class target enrichment products with our advanced machine-learning based analytics. This will simplify validation of future NGS tests to meet hospitals’ needs for high quality diagnostics.” 

Dr. Joseph A. Walder, IDT founder and CEO, commented, “We are proud of this partnership with Sophia Genetics. Sophia’s technology has triggered rapid advances in clinical genomics in recent years. With more labs and hospitals joining the clinical genomics community, we are confident Sophia Genetics is an ideal partner as we extend our target capture solutions to healthcare institutions in Europe for the ultimate benefit of patients.” 

The first bundle solution to be launched will be for diagnosis of hereditary cancers, such as breast, ovarian, and colon cancers. Future solutions will target leukaemia and cardiac disease. With this partnership, Sophia Genetics and IDT are taking a pragmatic approach in helping hospitals address their need to adopt NGS tests for routine clinical diagnostics. The partnership also establishes a foundation for additional growth in this area.
Advertisement